**Uniform Formulary**

**Pre-Proposal Teleconference**

**August 23, 2016**

**11:00pm MDT to 12:00pm MDT**

**Covering Quotes for the**

**November 16-17, 2016**

**DoD P&T Committee Reviews**

1. Attendance

Dr. Chris Conrad – Strategic Sourcing / Industry Liaison, DHA Pharmacy Operations Division – San Antonio, TX

Bruce Mitterer – Contracting Officer - DHA Contract Management – Aurora, CO

Matthew Halbe – Contract Analyst – DHA Contract Management – Aurora, CO

1. New RFQ Website: http://www.health.mil/About-MHS/Other-MHS-Organizations/DoD-PT-Committee/Drug-Classes-New-Drugs-Under-Review/November-2016
2. Drug Classes:
   1. **Anticoagulants – Oral Anticoagulants**
   2. **Antilipidemics – PCSK9s**
   3. **Designated Newly Approved Drug**
      1. **Spiriva Respimat (Class: Pulmonary-2 Agent, Subclass: Long Acting Muscarinic Agent)**
3. Quote Submissions
4. Due date for all original quotes and email duplicates is September 30, 2016 at 11:00 AM MDT. Any quote submitted after that will be considered late and will not be accepted. Suppliers are encouraged to submit their quotes early. For overnight delivery, it is suggested suppliers use FedEx Priority mail.
5. RFQ Point of Contact:
   * 1. Request for Quotation:
        1. General Inbox: [dha.detrick.cod-a.mbx.dha-uf-bpa-official@mail.mil](mailto:dha.detrick.cod-a.mbx.dha-uf-bpa-official@mail.mil)
     2. Industry Technical Liaison:
        1. General Inbox: <mailto:dha.jbsa.tricare-south.mbx.strategic-sourcing-rph@mail.mil>
     3. We have a change in personnel and will do so again, please be sure to use the generic email addresses listed above.
6. Other
   * 1. Documents are fillable
     2. An original signed BPA and ADP quote submitted for each different drug.

All RFQ documents (BPA Template and Appendices) are locked to prevent unnecessary editing. However, the appropriate fields allow the supplier to fill in where they need to. Fill in the appropriate fields before printing out the documents for submission.

For Example: The fillable fields allow you to type in your company information while keeping the integrity of the document intact.

* + 1. Do not print duplex for original quotes. Submit all hard copies as single-sided pages. Avoid double-sided quotes.

1. Lessons Learned: Responsiveness

It is important that suppliers respect the process that is in place by carefully reading the BPA, VARR and all instructions that accommodate it to ensure the quoting procedure is properly followed.

Past Reasons for non-responsive:

| **Non-Responsive Reason** | **Citation** |
| --- | --- |
| Company does not hold an FSS contract, or the FSS contract has expired | UF BPA Paragraph 10 “The company must have an existing FSS Contract for any pharmaceutical agent(s) quoted in this UFBPA at the time the quote is submitted, and at the time the UFBPA is executed” |
| Signed BPA terms and conditions is not submitted on time | http://www.health.mil/About-MHS/Other-MHS-Organizations/DoD-Pharmacy-and-Therapeutics-Committee/Drug-Classes-New-Drugs-Under-Review/February-2016 |
| Price per dosage unit will be the same for all package sizes | BPA Paragraph 8.b |

Company name on the BPA will be the company that receives the BPA, and must match the FSS. No subsidiaries, affiliates, or DBA’s are allowed.

1. IMPORTANT Info
   1. DHA Contracting welcomes all feedback regarding our reformatted web page and RFQ. Please contact the RFQ POC if there is any feedback from industry
   2. Those with existing BPAs for the agents being reviewed must submit new quotes since all BPAs in that class will end upon approval of that class review.

**Questions During Teleconference:**

Q: In the RFQ, does the term “STEP” refer to the other competitor in the PCSK9 class. The PA’s for both products currently have steps built in for Statins and Zetia.

A: Yes, the term “STEP” refers to the other competitor in the PCSK9 class. The current steps built in for statins and Zetia will remain in place unless the Committee recommends otherwise.